Tonghua Dongbao Pharmaceutical (600867) Stock Price, News, Quotes-Moomoo

CN Stock MarketDetailed Quotes

600867 Tonghua Dongbao Pharmaceutical

Watchlist

8.42
-0.18-2.09%

Not Open Dec 13 15:00 CST

16.69BMarket Cap48.95P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Adocia SA - Phase 3 Topline Results Expected in H1 2025
ReutersDec 12 12:01 ET
ADOCIA and Tonghua Dongbao Announce the Final Dosing in a Phase 3 Clinical Study of BioChaperone Lispro, Milestone Associated With a $10 Million Payment
BusinesswireDec 12 12:00 ET
Tonghua Dongbao Pharmaceutical Co., Ltd.'s (SHSE:600867) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?
Simply Wall StDec 12 01:07 ET
Tonghua Dongbao Pharmaceutical Completes Phase 1a Trial for Diabetes Injection
MT NewswiresDec 9 05:08 ET
Tonghua Dongbao Pharmaceutical (600867.SH): The THDBH120 has received the summary report of phase I clinical trial, and the research results have reached the main endpoint objectives.
Tonghua Dongbao Pharmaceutical (600867.SH) issued a statement that its wholly-owned subsidiary Dongbao Zixing (Hangzhou) Biomedical Co., Ltd...
Zhitong FinanceDec 6 02:35 ET
Tonghua Dongbao Pharmaceutical (600867.SH) has repurchased 0.98% of its shares at a cost of 0.149 billion yuan.
tonghua dongbao pharmaceutical (600867.SH) announced that as of the end of November 2024, the company had completed the centralized bidding transaction...
Zhitong FinanceDec 2 03:09 ET

Comments

Moomoo AI

Jan 5 19:16

Investor expectations of limited future growth might have led to Tonghua Dongbao Pharmaceutical's lower P/E ratio. The reduced possibility of significant share price increases speaks to the company's dimmed earnings outlook, which also contributes to the low P/E.

Insufficient Growth At Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Hampers Share Price

Moomoo AI

Dec 15, 2023 17:09

Tonghua Dongbao Pharmaceutical shows promising performance with its high rate of return and reinvestment, resulting in significant earnings growth. Consider reviewing the company's stock price valuation and earnings growth for investment opportunities.

Tonghua Dongbao Pharmaceutical Co., Ltd.'s (SHSE:600867) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Moomoo AI

Nov 23, 2023 19:05

Tonghua Dongbao Pharmaceutical's EPS and revenue saw a dip, but share prices still rose, indicating that investors might be considering factors other than EPS. The annual shareholder return was 38%, primarily from dividends, significantly outperforming the 1.1% TSR loss over five years.